Key Highlights

  • Shares are trading up 11.89% at $68.12 versus a prior close of $60.88.
  • The board authorized repurchases of up to $500 million of common stock.
  • Third-quarter Revenue reached $357.8 million, up about 70% year over year.

PTC Therapeutics (NASDAQ:PTCT) shares are trading up 11.89% at $68.12 today after the board authorized a share repurchase program of up to $500 million. The stock is recovering part of its post-earnings drop, which took it down about 7% last week, and sits within a 52-week range of $58.80 to $90.87 on Volume of roughly 1.8 times average.

PTC Therapeutics is a Warren, New Jersey-based global biopharmaceutical company founded in 1998 that develops and commercializes medicines for children and adults with rare genetic disorders. Its commercial portfolio includes Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, Kebilidi/Upstaza for AADC deficiency, and Tegsedi and Waylivra in Latin America, and it earns royalties from Roche's Evrysdi for spinal muscular atrophy.

Repurchase Plan Gives Management Flexibility on Timing

Under the authorization, repurchases may be made from time to time at management's discretion through open-market transactions including pre-set trading plans, privately negotiated transactions, accelerated share repurchases and other methods. The program is subject to market conditions, and Buybacks are discretionary with no set timing.

Chief Executive Matthew Klein called the shares a compelling opportunity and said the program reflects deep conviction in the company's near- and long-term growth. He added that PTC will maintain the financial flexibility to support existing programs and pursue potential value-creating Business development transactions.

Sephience Growth and Royalties Anchor a Strong Third Quarter

The authorization follows a third-quarter report with revenue of $357.8 million, up about 70% year over year, driven by Sephience and Evrysdi royalties. The company raised its 2026 guidance and held about $2.13 billion in cash, though it also posted a quarterly loss that sent the stock lower after the report.

Sephience's strong launch has driven rapid growth, taking total revenue from $273 million in the first quarter to $358 million in the third. Several analysts, including Citi, TD Cowen, RBC and Wells Fargo, recently nudged price targets higher.

Pipeline Includes Huntington's Disease and Fabry Programs

The pipeline includes the Huntington's disease candidate PTC518, partnered with Novartis, vatiquinone for Friedreich's ataxia and the newly acquired Fabry disease gene therapy ST-920. The move comes as the healthcare sector ETF is flat to slightly lower.

Execution on the Buyback Will Shape the Rebound

With a $500 million authorization against about $2.13 billion in cash, PTC has room to repurchase shares while funding its pipeline. Investors will watch how quickly it deploys the program as the stock works its way back from last week's post-earnings decline.